Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The same trial that sent Summit up 272% sees the stock crash 36%.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
But sasanlimab's use looks set to remain narrow.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
